Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 studyJuan Pablo Alderuccio, Paolo F. Caimi, Kirit M. Ardeshna et al.|Blood Advances|2022Cited by 6
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical TrialJuan Pablo Alderuccio, Paolo F. Caimi, Weiyun Z. Ai et al.|Blood|2021Cited by 3